-
Mashup Score: 6Vaccination of Adults With Cancer: ASCO Guideline - 1 month(s) ago
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaim
Source: ascopubs.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in 2 % to 7 % of the non-small cell lung cancer (NSCLC) patient population [1–3]. Identification of ALK gene rearrangements in NSCLC is clinically important as tumors harboring this genomic alteration are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) [3]. According to international guidelines, the preferred first-line treatment option for patients with ALK-positive metastatic NSCLC includes second-generation ALK TKIs, alectinib or brigatinib, or the third-generation ALK TKI, lorlatinib [4,5].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3 - 2 month(s) ago
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline. PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS This ASCO living guideline offers continua
Source: ascopubs.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
The tumor, node and metastasis (TNM) classification of lung cancer is periodically revised. The International Association for the Study of Lung Cancer collected and analyzed a new database to inform the forthcoming 9th edition of the TNM classification. The results are herewith presented.
Source: www.jto.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 38Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel - 2 month(s) ago
Working groups of the European Leukemia Net (ELN) have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different c
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 35Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel - 2 month(s) ago
Working groups of the European Leukemia Net (ELN) have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different c
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar - 3 month(s) ago
Adoptive cell therapy (ACT) has been demonstrated to be one of the most promising cancer immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells to overexpress chimeric antigen receptors (CARs), for example, has shown potent efficacy in the therapy of some hematologic malignancies. However, the efficacy of chimeric antigen receptor T cell (CAR-T) therapy against solid tumors is still limited due to the immunosuppressive tumor microenvironment (TME) of solid tumors, difficulty in infiltrating tumor sites, lack of tumor-specific antigens, antigen escape, and severe side effects. In contrast, macrophages expressing CARs (CAR-macrophages) have emerged as another promising candidate in immunotherapy, particularly for solid tumors. Now at its nascent stage (with only one clinical trial progressing), CAR-macrophage still shows inspiring potential advantages over CAR-T in treating solid tumors, including more abundant antitumor mechanisms and better infil
Source: www.bjbms.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 23
Description: The purpose of this updated guidance statement is to guide clinicians on screening for colorectal cancer (CRC) in asymptomatic average-risk adults. The intended audience is all clinicians. The population is asymptomatic adults at average risk for CRC. Methods: This updated guidance statement was developed using recently published and critically appraised clinical guidelines from national guideline developers since the publication of the American College of Physicians’ 2019 guidance statement, “Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults.” The authors searched for national guidelines from the United States and other countries published in English using PubMed and the Guidelines International Network library from 1 January 2018 to 24 April 2023. The authors also searched for updates of guidelines included in the first version of our guidance statement. The Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument was used to assess
Source: www.acpjournals.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 7Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia - 4 month(s) ago
Abstract. T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL) is a rare hematologic malignancy most commonly affecting adolescent and youn
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 7Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia - 4 month(s) ago
Abstract. T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL) is a rare hematologic malignancy most commonly affecting adolescent and youn
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
Vaccination of adults with cancer: ASCO Guideline https://t.co/d1ifEoWpgB https://t.co/QM2YhNveZ4